Philadelphia’s juries seem to be persuaded by the arguments presented by hormone therapy litigation plaintiffs in their products liability actions against a locally based pharmaceuticals giant, but the city’s judges don’t.

A ruling Wednesday by Philadelphia Common Pleas Senior Judge Ricardo C. Jackson granting the defense judgment NOV in Nelson v. Wyeth means that the first hormone therapy case to reach trial in the city’s Complex Litigation Center has effectively ended with a Wyeth victory despite a sizable jury award in favor of the plaintiffs.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Advance® Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]